ArticleBMC infectious diseases2024
Clinical efficacy of macrolide antibiotics in mycoplasma pneumoniae pneumonia carrying a macrolide-resistant mutation in the 23 S rRNA gene in pediatric patients.
Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Qingxuan Zhike Granules Modulate Gut Dysbiosis and Enhance Intestinal Repair in MurineJournal of microbiology and biotechnology · 2026Article
- Associations of Mycoplasma pneumoniae load, co-infections, and macrolide resistance with clinical-laboratory profiles in hospitalized pediatric pneumonia: a targeted next-generation sequencing study of bronchoalveolar lavage fluid.Annals of clinical microbiology and antimicrobials · 2026Article
- Association between normalizedTranslational pediatrics · 2026Article
- Association between 23S rRNA gene positivity and clinical characteristics in patients with mycoplasma pneumoniae pneumonia.BMC pediatrics · 2026Article
- Metagenomic and Targeted Next-Generation Sequencing in Infectious Disease Diagnostics: Current Applications, Challenges, and Future Perspectives.Diagnostics (Basel, Switzerland) · 2026Review
- Construction of a nomogram combining CT and serum markers for predicting macrolide resistance gene mutation status in pediatric Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
- Admission-time immunologic patterns in hospitalized children withFrontiers in pediatrics · 2026Article
- Clinical characteristics of hospitalized children with mycoplasma pneumoniae pneumonia in Chinese tertiary hospitals during the 2023-2024 post-pandemic period.Frontiers in cellular and infection microbiology · 2026Article
- From genes to clinical application: a circulating four-gene signature for early diagnosis model of refractoryFrontiers in cellular and infection microbiology · 2026Article
- Characterizing the epidemiology ofEmerging microbes & infections · 2025Article
- A one-pot, visual, multiplex microfluidic digital PCR chip for simultaneous point-of-care detection, genotyping, and macrolide resistance assessment of Mycoplasma pneumoniae.Mikrochimica acta · 2025Article
- Macrolide-resistant Mycoplasma pneumoniae pneumonia in Chinese children: a retrospective study of clinical features and prognosis.Italian journal of pediatrics · 2025Article
- Clinical diagnostic value of throat swabs in pediatric acute lower respiratory tract infections using targeted next-generation sequencing.BMC pediatrics · 2025Article
- Analysis of the characteristics of mixed infections with Mycoplasma pneumoniae in children.Scientific reports · 2025Article
- Antimicrobial prescription KAP among physicians in primary care institutions in Southwest China.PloS one · 2025Article
- Clinical Manifestations, Macrolide Resistance, and Treatment Utilization Trends ofMicroorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe global prospective surveillance data showed the re-emergence of mycoplasma pneumoniae pneumonia (MPP) in Europe and Asia after the coronavirus disease 2019 pandemic. We sought to observe the effect of macrolide antibiotics in the treatment of MPP carrying a macrolide-resistant mutation gene and the potential of targeted next-generation sequencing (tNGS) as a front-line diagnostic in MPP patients.
methodsThe baseline characteristics of 91 children with MPP hospitalized from January to October 2023 were retrospectively analyzed. They were divided into two groups according to whether carrying the macrolide-resistant mutation or not. The logistic and linear regression analyses were used to determine whether the mutation was a standalone predictive predictor of the duration of fever and hospital length of stay.
resultsFirst, no patients had a fever for ≥ 7 days after macrolide treatment. But length of stay and hormone concentration were significantly different between the two groups (P < 0.05). There were also no statistical association between the mutation and the duration of fever and hospital length of stay.
conclusionMacrolides can be administered to MPP children carrying a macrolide-resistant mutation. tNGS can be seen as a front-line diagnostic in MPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.